PURPOSE: The purpose of this study was to assess two-step in vivo tumor targeting by specific biotin-conjugated antibodies and ultrasmall superparamagnetic iron oxide (USPIO)-anti-biotin nanoparticles as contrast agents for magnetic resonance imaging (MRI) at 1.5 T. PROCEDURES: D430B human lymphoma cells, expressing the CD70 surface antigen, were injected either s.c. or i.v. to induce pseudo-metastases in NOD/SCID mice. Thirty micrograms of biotin-conjugated monoclonal anti-CD70 was injected i.v., followed 4 h later by 8 micromol Fe/Kg USPIO-anti-biotin. After 24 h, MRI was performed on T2* and b-FFE sequences. Signal intensity (SI) was calculated before and after USPIO-anti-biotin administration. RESULTS: Subcutaneous xenografts showed a dishomogeneous 30% decrease in SI on T2* with anti-CD70 + USPIO-anti-biotin treatment. Pseudo-metastatic xenografts showed a slight reduction in SI on T2*, but a 60% decrease in SI on b-FFE-weighted sequences. Prussian blue staining confirmed the presence of iron nanoparticles in the excised tumors. CONCLUSION: MRI at 1.5 T can detect tumors by a two-step in vivo biotin-based protocol, which may allow the targeting of any cell surface antigen.
PURPOSE: The purpose of this study was to assess two-step in vivo tumor targeting by specific biotin-conjugated antibodies and ultrasmall superparamagnetic iron oxide (USPIO)-anti-biotin nanoparticles as contrast agents for magnetic resonance imaging (MRI) at 1.5 T. PROCEDURES: D430B humanlymphoma cells, expressing the CD70 surface antigen, were injected either s.c. or i.v. to induce pseudo-metastases in NOD/SCIDmice. Thirty micrograms of biotin-conjugated monoclonal anti-CD70 was injected i.v., followed 4 h later by 8 micromol Fe/Kg USPIO-anti-biotin. After 24 h, MRI was performed on T2* and b-FFE sequences. Signal intensity (SI) was calculated before and after USPIO-anti-biotin administration. RESULTS: Subcutaneous xenografts showed a dishomogeneous 30% decrease in SI on T2* with anti-CD70 + USPIO-anti-biotin treatment. Pseudo-metastatic xenografts showed a slight reduction in SI on T2*, but a 60% decrease in SI on b-FFE-weighted sequences. Prussian blue staining confirmed the presence of iron nanoparticles in the excised tumors. CONCLUSION: MRI at 1.5 T can detect tumors by a two-step in vivo biotin-based protocol, which may allow the targeting of any cell surface antigen.
Authors: Bruce F Israel; Margaret Gulley; Sandra Elmore; Silvano Ferrini; Wen-hai Feng; Shannon C Kenney Journal: Mol Cancer Ther Date: 2005-12 Impact factor: 6.261
Authors: Pavla Jendelová; Vít Herynek; Lucia Urdziková; Katerina Glogarová; Sárka Rahmatová; Ivan Fales; Benita Andersson; Pavel Procházka; Josef Zamecník; Tomás Eckschlager; Petr Kobylka; Milan Hájek; Eva Syková Journal: Cell Transplant Date: 2005 Impact factor: 4.064
Authors: P L Tazzari; D de Totero; A Bolognesi; N Testoni; S Pileri; S Roncella; G Reato; H Stein; M Gobbi; F Stirpe Journal: Haematologica Date: 1999-11 Impact factor: 9.941
Authors: Julie A McEarchern; Ezogelin Oflazoglu; Leigh Francisco; Charlotte F McDonagh; Kristine A Gordon; Ivan Stone; Kerry Klussman; Eileen Turcott; Nico van Rooijen; Paul Carter; Iqbal S Grewal; Alan F Wahl; Che-Leung Law Journal: Blood Date: 2006-10-12 Impact factor: 22.113
Authors: Pavla Jendelová; Vít Herynek; Lucia Urdzíková; Katerina Glogarová; Jana Kroupová; Benita Andersson; Vítezslav Bryja; Martin Burian; Milan Hájek; Eva Syková Journal: J Neurosci Res Date: 2004-04-15 Impact factor: 4.164
Authors: S Ferrini; C Cantoni; E Ciccone; R Biassoni; I Prigione; C Bottino; P Venzano; L Moretta Journal: Eur J Immunol Date: 1991-09 Impact factor: 5.532
Authors: Jaehoon Chung; Kehkooi Kee; Joëlle K Barral; Rajesh Dash; Hisanori Kosuge; Xi Wang; Irving Weissman; Robert C Robbins; Dwight Nishimura; Thomas Quertermous; Renee A Reijo-Pera; Phillip C Yang Journal: Magn Reson Med Date: 2011-05-20 Impact factor: 4.668